Catabasis Pharmaceuticals has filed for an IPO with a proposed offering amount of $75 million. The company will list shares on the NASDAQ under the symbol CATB. The clinical stage biopharma is focused on the discovery, development and commercialization of therapeutics based on its linker technology platform. Its current candidates look to treat a type of muscular dystrophy and hypercholesterolemia, among other diseases. Catabasis last raised funding in March, when it received $12.4 million at a valuation of $134 million. Backers include SV Life Sciences (25.8% pre-IPO stake), Clarus Ventures (24.9%) and MedImmune Ventures (14.8%).